中国神经再生研究(英文版)

中国神经再生研究(英文版) ›› 2012, Vol. 7 ›› Issue (22): 1685-1687.

• 观点:脊髓损伤修复保护与再生 •    下一篇

Breaking News in Spinal Cord Injury Research FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries

  

  • 出版日期:2012-08-05 发布日期:2012-08-05

Breaking News in Spinal Cord Injury Research FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries

Xiao-Ming Xu   

  1. Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute & Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA
  • Online:2012-08-05 Published:2012-08-05
  • Contact: Xiao-Ming Xu, Ph.D., Professor, Spinal Cord and Brain Injury Research Group, Stark Neurosciences Research Institute & Department of Neurological Surgery, Indiana University School of Medicine, Indianapolis, IN 46202, USA xu26@iupui.edu
  • About author:Xu XM. Breaking News in Spinal Cord Injury Research: FDA Approved Phase I Clinical Trial of Human, Autologous Schwann Cell Transplantation in Patients with Spinal Cord Injuries. Neural Regen Res. 2012;7(22):1685-1687.

PDF

815

Abstract:

On July 31, 2012, The Miami Project to Cure Paralysis at the University of Miami Miller School of Medicine received permission from the Food and Drug Administration (FDA) to begin a Phase I clinical trial to evaluate the safety of transplanting human autologous Schwann cells to treat patients with spinal cord injuries. This is the only FDA-approved cell therapy-based clinical trial for sub-acute spinal cord injury in the United States.